Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea

British Journal of Dermatology

Volumn 162, Issue 5, 2010, Pages 1056-1063

  Antiga, E ^a   Quaglino, P ^b   Bellandi, S ^a   Volpi, W ^a   Del Bianco, E ^a   Comessatti, A ^b   Osella Abate, S ^b   De Simone, C ^c   Marzano, A ^d   Bernengo, M G ^b   Fabbri, P ^a   Caproni, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

FoxP3; Morphoea; Regulatory cytokines; Regulatory T cells; Systemic sclerosis

Indexed keywords

CYTOKINE; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHEA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SKIN DEFECT; SYSTEMIC SCLEROSIS;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77951238591     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09633.x     Document Type: Article

References (49)

1. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol 2006 24 : 374 392. (Pubitemid 44332868)
2. Bournia VK, Vlachoyiannopoulos PG, Selmi C et al. Recent advances in the treatment of systemic sclerosis. Clin Rev Allergy Immunol 2009 36 : 176 200.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009 360 : 1989 2003.
4. Gu YS, Kong J, Cheema GS et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008 38 : 132 160.
5. Sgonc R, Gruschwitz MS, Dietrich H et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996 98 : 785 792. (Pubitemid 26349184)
6. Kessler D, Dethlefsen S, Haase I et al. Fibroblasts in mechanically stressed collagen lattices assume a 'synthetic' phenotype. J Biol Chem 2001 276 : 36575 36585. (Pubitemid 37384270)
7. Cepeda EG, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004 16 : 723 732.
8. Kalogerou A, Gelou E, Mountantonakis S et al. Early T-cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005 64 : 1233 1235. (Pubitemid 41113366)
9. Ishikawa H, Takeda K, Okamoto A et al. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4(+) T cells. J Invest Dermatol 2009 129 : 1688 1695.
10. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003 3 : 253 257.
11. La Cava A. Natural Tregs and autoimmunity. Front Biosci 2009 14 : 333 343.
12. Apostolou I, Verginis P, Kretschmer K et al. Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol 2008 28 : 619 624.
13. Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006 212 : 8 27.
14. Torgerson TR. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 2006 28 : 63 76. (Pubitemid 44267960)
15. Caproni M, Torchia D, Antiga E et al. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006 26 : 370 375. (Pubitemid 44051384)
16. Franz B, Fritzsching B, Riehl A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007 56 : 1910 1920. (Pubitemid 47110390)
17. Bonelli M, von Dalwigk K, Savitskaya A et al. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis 2008 67 : 664 671. (Pubitemid 351571931)
18. Kuhn A, Beissert S, Krammer PH. CD4(+)CD25(+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 2009 301 : 71 81.
19. Banica L, Besliu A, Pistol G et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009 42 : 41 9.
20. Radstake TR, van Bon L, Broen J et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE 2009 4 : e5981.
21. Hudson M, Taillefer S, Steele R et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007 25 : 754 757. (Pubitemid 350284851)
22. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15 : 202 205. (Pubitemid 18073738)
23. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001 167 : 1245 1253.
24. Braitch M, Harikrishnan S, Robins RA et al. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009 119 : 239 245.
25. Chen X, Oppenheim JJ, Winkler-Pickett RT et al. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006 36 : 2139 2149. (Pubitemid 44251759)
26. Bhattacharyya S, Chen SJ, Wu M et al. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008 173 : 1085 1099.
27. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci 2009 1 : 226 235.
28. Gabrielli A, Di Loreto C, Taborro R et al. Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993 68 : 340 349. (Pubitemid 23284094)
29. Gilmour TK, Wilkinson B, Breit SN, Kossard S. Analysis of dendritic cell populations using a revised histological staging of morphoea. Br J Dermatol 2000 143 : 1183 1192. (Pubitemid 32052753)
30. Peltonen J, Kähäri L, Jaakkola S et al. Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990 94 : 365 371. (Pubitemid 20061648)
31. Giacomelli R, Cipriani P, Danese C et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol 1996 23 : 291 296. (Pubitemid 26078385)
32. Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004 138 : 540 546. (Pubitemid 39573637)
33. Keystone E, Lok C, Appleton B et al. Elevated serum levels of TGFβ in patients with scleroderma. Arthritis Rheum 1992 35 (Suppl.) : 206 [Abstr.]
34. Snowden N, Coupes B, Herrick A et al. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis 1994 53 : 763 767. (Pubitemid 2151095)
35. Higley H, Persichitte K, Chu S et al. Immunocytochemical localization and serologic detection of transforming growth factor beta-1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994 37 : 278 288. (Pubitemid 24979511)
36. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001 27 : 140 146. (Pubitemid 32781022)
37. Choi J, Min D, Cho M et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003 30 : 1529 1533. (Pubitemid 36835451)
38. Coral-Alvarado P, Quintana G, Garces MF et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 2009 29 : 1017 1024.
39. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 2003 3 (Suppl. 29 S32 8. (Pubitemid 41116909)
40. Dziadzio M, Smith RE, Abraham DJ et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology 2005 44 : 1518 1524. (Pubitemid 41742468)
41. Warrington KJ, Nair U, Carbone LD et al. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 2006 8 : R136.
42. Cicuttini FM, Byron KA, Maher D et al. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol Int 1995 14 : 201 206.
43. Kucharz EJ, Brzezinska-Wcislo L, Kotulska A et al. Elevated serum level of interleukin-10 in patients with systemic sclerosis. Clin Rheumatol 1997 16 : 638 639. (Pubitemid 28341477)
44. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994 94 : 2489 2492. (Pubitemid 24379626)
45. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001 281 : 200 205. (Pubitemid 32924419)
46. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit Rev Immunol 2000 20 : 1 16. (Pubitemid 30191900)
47. Mowat AM, Parker LA, Beacock-Sharp H et al. Oral tolerance: overview and historical perspectives. Ann N Y Acad Sci 2004 1029 : 1 8. (Pubitemid 40298509)
48. Ilan Y, Gotsman I, Pines M et al. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model. Blood 2000 95 : 3613 3619. (Pubitemid 30428500)
49. Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients. Med Sci Monit 2004 10 : CR202 8. (Pubitemid 38787629)